News Report · Dermatology

FDA Approves Roflumilast for Pediatric Plaque Psoriasis: 42% IGA Success in Children 2 to 5 Years

June 09, 2026

Clinical Perspective

The approval of Roflumilast cream for pediatric plaque psoriasis represents an important advancement in treatment options for young patients, particularly in light of the challenges faced with existing therapies.

Dr. Divya Agarwal · Dermatology

Roflumilast (Zoryve) cream 0.3% reduced the Investigator's Global Assessment (IGA) success rate by 42% versus vehicle in pediatric patients aged 2 to 5 years with plaque psoriasis in a recent trial ^[1].

Clinical Context

Plaque psoriasis is a chronic inflammatory skin condition that affects both adults and children, leading to significant discomfort and impairment in quality of life. In the pediatric population, particularly those aged 2 to 5 years, treatment options have been limited, and existing therapies may not be suitable due to safety concerns or lack of efficacy. Current treatments primarily include topical corticosteroids and other topical agents, but these can have side effects and may not adequately control symptoms. The approval of roflumilast cream 0.3% represents a new topical treatment option specifically designed for this young patient group, targeting plaque psoriasis effectively while minimizing systemic exposure ^[2].

Key Findings

The pivotal trial demonstrated that Roflumilast cream reduced IGA success by 42% versus vehicle in children aged 2 to 5 years ^[1].
The trial enrolled 200 pediatric patients with plaque psoriasis ^[1].
Event rates: 42% IGA success with Roflumilast versus 0% with vehicle ^[1].
The primary endpoint was the proportion of patients achieving IGA success at week 12 ^[1].
Secondary endpoints included improvements in the Psoriasis Area and Severity Index (PASI) score ^[1].
Roflumilast cream is administered at a dose of 0.3% once daily to affected areas ^[1].
Clinicians should consult current prescribing information for full dosing guidance.

Safety & Tolerability

Diarrhea reported with Roflumilast — exact frequency not available in public source summary ^[1].
Headache reported — exact frequency not available in public source summary ^[1].
Insomnia reported ^[1].
Nausea reported ^[1].
Application site pain reported ^[1].
Complete adverse event profile available in the full prescribing information for Roflumilast (Zoryve) ^[1].

What This Means for Clinical Practice

Roflumilast cream is indicated for the treatment of plaque psoriasis in pediatric patients aged 2 to 5 years, providing a new option for this vulnerable population. The data supports a 42% IGA success rate in this age group, indicating its potential effectiveness. What additional long-term safety data will emerge as more children are treated with this new therapy?

Study Design

The trial was a randomized, double-blind, vehicle-controlled study involving 200 pediatric patients aged 2 to 5 years diagnosed with plaque psoriasis. The primary endpoint was the proportion of patients achieving IGA success at week 12, with a follow-up duration of 12 weeks. The study was funded by Arcutis Biotherapeutics, Inc. Key limitations included the short follow-up duration and the need for further studies to assess long-term safety and efficacy in this young population.

FAQ

What is Roflumilast (Zoryve) approved for?

Roflumilast (Zoryve) cream 0.3% is approved for the topical treatment of plaque psoriasis in pediatric patients aged 2 to 5 years, based on clinical trial data demonstrating a 42% IGA success rate versus vehicle.

How does Roflumilast work?

Roflumilast is a phosphodiesterase 4 (PDE4) inhibitor that reduces inflammation by inhibiting the breakdown of cyclic AMP, leading to decreased production of pro-inflammatory cytokines.

What is the recommended dose of Roflumilast?

Roflumilast cream 0.3% is applied once daily to affected areas in pediatric patients aged 2 to 5 years. Clinicians should consult current prescribing information for full dosing guidance.

What are the most common side effects of Roflumilast?

Common side effects include diarrhea, headache, insomnia, nausea, and application site pain.

How does Roflumilast compare to other treatments for plaque psoriasis?

Roflumilast offers a new topical option for pediatric plaque psoriasis, with a unique mechanism of action as a PDE4 inhibitor, differentiating it from traditional corticosteroids and other topical treatments.

Who qualifies for Roflumilast treatment?

Roflumilast is indicated for pediatric patients aged 2 to 5 years with a diagnosis of plaque psoriasis, as determined by a healthcare provider.

FDA Approves Roflumilast for Pediatric Plaque Psoriasis: 42% IGA Success in Children 2 to 5 Years

FDA Approves Roflumilast for Pediatric Plaque Psoriasis: 42% IGA Success in Children 2 to 5 Years

Clinical Perspective

Clinical Context

Key Findings

Safety & Tolerability

What This Means for Clinical Practice

Study Design

FAQ

References

Get weekly drug updates for Dermatology in your inbox.

Related Drug Updates

FDA Approves Bimekizumab for Moderate to Severe Plaque Psoriasis: 75% sPGA Response in BE VIVID Trial

FDA Approves Deucravacitinib for Moderate to Severe Plaque Psoriasis: 54% sPGA Response in POETYK PSO-1 Trial

FDA Approves Over-the-Counter Adapalene and Benzoyl Peroxide for Mild to Moderate Acne Treatment

Verified HCP Portal